Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?

被引：0
作者：
Pier Paolo M. Berton Giachetti
Giuseppe Curigliano
机构：
[1] Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS),Division of Early Drug Development for Innovative Therapy, European Institute of Oncology
[2] University of Milan,Department of Oncology and Hemato
来源：
Nature Reviews Clinical Oncology | 2024年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Recent results from the phase III PHILA trial demonstrate a benefit in terms of progression-free survival derived from the addition of pyrotinib to first-line chemotherapy plus trastuzumab in patients with metastatic HER2-positive breast cancer. Dual HER2 blockade with pyrotinib and trastuzumab is an effective therapeutic strategy but might increase the risk of gastrointestinal toxicity; therefore, the risk-to-benefit ratio should be carefully evaluated.
引用
收藏
页码：171 / 172
页数：1
相关论文
共 10 条
  • [1] Swain SM(2020)Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Lancet Oncol. 21 519-530
  • [2] Ma F(2023)Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial BMJ 383 82-92
  • [3] Gion M(2022)Systemic therapy for HER2-positive metastatic breast cancer: moving into a new era Am. Soc. Clin. Oncol. Educ. Book 42 503-513
  • [4] Xu B(2023)Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): final analysis of a phase III, randomized, double-blind, placebo-controlled study Breast Cancer Res. Treat. 197 485-492
  • [5] McCullough AE(2014)Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study Breast Cancer Res. Treat. 143 793-800
  • [6] Garrett JT(2011)Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications Cancer Biol. Ther. 11 351-360
  • [7] Arteaga CL(2021)Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial Lancet Oncol. 22 803-814
  • [8] Xu B(2009)Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity Oncogene 28 2110-2120
  • [9] Scaltriti M(2023)Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial Nat. Med. 29 undefined-undefined
  • [10] Mosele F(undefined)undefined undefined undefined undefined-undefined
1